[go: up one dir, main page]

KR950701818A - 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues) - Google Patents

탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)

Info

Publication number
KR950701818A
KR950701818A KR1019940704525A KR19940704525A KR950701818A KR 950701818 A KR950701818 A KR 950701818A KR 1019940704525 A KR1019940704525 A KR 1019940704525A KR 19940704525 A KR19940704525 A KR 19940704525A KR 950701818 A KR950701818 A KR 950701818A
Authority
KR
South Korea
Prior art keywords
arg
leu
gly
lys
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019940704525A
Other languages
English (en)
Inventor
낸시 엠. 리
호레이스 엠. 로
아키라 이. 다께모리
Original Assignee
원본미기재
데스-티 아이알 다이놀핀 파트너쉽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 데스-티 아이알 다이놀핀 파트너쉽 filed Critical 원본미기재
Publication of KR950701818A publication Critical patent/KR950701818A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명의 신규한 펩타이드는 다이놀핀 동족체로서 내인성 다이놀핀과 유사한 활성을 갖지만 내인성 다이놀핀과 관련하여 탈-Try 또는 탈-Try-Gly된 것이다. 이 펩타이드는 마약성 진통제의 활성에 상승작용을 하도록 하고 및/또는 금단증상을 차단하도록 마약성 진통제에 내성을 갖는 숙주에서 투여하는 치료적인 용도를 갖는다.

Description

탈-TYR 다이놀핀 동족체(DES-TYR DYNORPHIN ANALOGUES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 서열을 갖는 펩타이드 :
    Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn (SEQ IN NO :4) ;Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp (SEQ IN NO: 5) ;Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp(SEQ IN NO:6) ;Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (SEQ IN NO:7);Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu(SEQ IN NO:8);Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys(SEQ IN NO:9);Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro(SEQ IN NO:10);Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg(SEQ IN NO:11); 여기서, C-말단은 산 또는 아미드형태이다.
  2. 하기 서열을 갖는 펩타이드;
    Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln (SEQ IN NO :13);Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn (SEQ IN NO :14);Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp(SEQ IN NO :15);Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp(SEQ IN NO :16);Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys(SEQ IN NO :17);Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu(SEQ IN NO :18);
  3. 마약성 진통제 금단증상을 차단하고 및/또는 마약성 진통제와 함께 투여되어 상승작용을 일으키도록 하는 데 효과적인 양의 다이놀핀 동족체를 투여하는데 투여된 다이놀핀 동족체가 N-말단에서 탈-Tyr또는 탈-Tyr-Gly인 것을 포함하는, 마약성 진통제가 내성을 갖는 환자의 치료방법.
  4. 제10항에 있어서, 다이놀핀 동족제가 약제학적으로 수용가능한 용액에 투여되는 치료방법.
  5. 제10항에 있어서, 다이놀핀 동족제가 최소한 6아미노산 잔기를 갖는 치료방법.
  6. 제10항에 있어서, 다인놀핀, 다이놀핀 동족제가 C-말단에서 아미드화 되는 치료방법.
  7. 제10항에 있어서, 다이놀핀 동족제가 내인성 다이놀핀의 아미노산 서열에 비하여 증가된 생체내 안정성 또는 배좌안정성을 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940704525A 1992-06-12 1993-06-01 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues) Withdrawn KR950701818A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89792092A 1992-06-12 1992-06-12
US07/897,920 1992-06-12
PCT/US1993/005161 WO1993025217A1 (en) 1992-06-12 1993-06-01 Des-tyr dynorphin analogues

Publications (1)

Publication Number Publication Date
KR950701818A true KR950701818A (ko) 1995-05-17

Family

ID=25408662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704525A Withdrawn KR950701818A (ko) 1992-06-12 1993-06-01 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)

Country Status (11)

Country Link
EP (1) EP0652765A4 (ko)
JP (1) JPH08501075A (ko)
KR (1) KR950701818A (ko)
AU (1) AU4399093A (ko)
CA (1) CA2137916A1 (ko)
CZ (1) CZ281630B6 (ko)
FI (1) FI945811L (ko)
HU (1) HUT70160A (ko)
NO (1) NO944778L (ko)
RU (1) RU95106651A (ko)
WO (1) WO1993025217A1 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
IL134796A0 (en) 1997-09-04 2001-04-30 Novoneuron Inc Noribogaine in the treatment of pain and drug addiction
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
EP1598365A1 (en) 1999-05-17 2005-11-23 ConjuChem Inc. Protection of endogenous therapeutic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
WO2002062844A2 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
EP1360202B1 (en) 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc PHOSPHATESTER OF NORIBOGAIN
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US10428115B2 (en) 2013-05-24 2019-10-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006626A1 (en) * 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus

Also Published As

Publication number Publication date
FI945811A7 (fi) 1995-02-06
NO944778L (no) 1995-02-10
EP0652765A4 (en) 1997-04-09
CZ313194A3 (en) 1995-08-16
JPH08501075A (ja) 1996-02-06
EP0652765A1 (en) 1995-05-17
NO944778D0 (no) 1994-12-09
HUT70160A (en) 1995-09-28
FI945811L (fi) 1995-02-06
RU95106651A (ru) 1996-12-27
CA2137916A1 (en) 1993-12-23
WO1993025217A1 (en) 1993-12-23
FI945811A0 (fi) 1994-12-09
AU4399093A (en) 1994-01-04
CZ281630B6 (cs) 1996-11-13
HU9403563D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
MX9402339A (es) Formulacion de proteina.
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
DK0772452T3 (da) Farmaceutisk formulering til subkutan, intramuskulær eller intradermal administration af faktor VIII
Klein et al. Pressor and cardioaccelerator effects of gamma MSH and related peptides
RU2223970C2 (ru) Лечение ожирения
KR900003205A (ko) 제약 화합물
US4684624A (en) Method of treating cerebral ischemia
KR960702847A (ko) 생물학적 활성의 바소프레신 유사체
SG129211A1 (en) Therapeutic molecules
KR920700227A (ko) 초고활성 인체 인슐린 동족체
KR880013974A (ko) 합성펩티드와 이를 포함하는 제약학적 조성물
US4481191A (en) Method for controlling blood pressure
DE60133654D1 (de) Arzneimittel enthaltend analgetische peptide
ES2842523T3 (es) Métodos y composiciones para el tratamiento de la artritis
Mann et al. Rotational syndrome after central injection of C-terminal 7-peptide of cholecystokinin
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
US5908832A (en) Peptide analog
KR900701839A (ko) Crf 유사체
EP0016136A1 (en) Inhibition by peptides of tolerance to and dependence on morphine
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
KR930012034A (ko) 급성 췌장염 치료용 브래디키닌-길항제
Takeuchi et al. Modification of effects of biologically active peptides, caused by enzyme treatment, on the excitability of identifiable giant neurones of an African giant snail (Achatina fulica Férussac)
KR960706503A (ko) CXC 인터크린 분자의 펩타이드 억제제(Peptide inhibitors of CXC intercrine molecules)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19941212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid